Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lumakras A Big Focus For Amgen; More Data Coming Soon

KRAS Inhibitor’s Q2 Sales Lumped In With ‘Other’ Products

Executive Summary

Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.

You may also be interested in...



Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

Early Assets Excite At Novartis R&D Day

NIBR chief Jay Bradner tells Scrip that the Swiss major's focus is on developing first in class therapies rather than 'fast-follower' research seen across the biopharma sector. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel